Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial assessing safety, tolerability, PK/PD of LCZ696 in pediatric heart failure, followed by a 52-week double-blind comparison with enalapril (Phase 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Enalapril (enalapril)
• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pediatric Heart Failure | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-02-10